AbbVie Inc
USUSDAbbVie Inc (US:ABBV) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 4. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site web
- abbvie.com
- Secteur
- Health Care · Biotechnology: Pharmaceutical Preparations
- Siège social
- North Chicago, United States
- PDG
- Robert A. Michael
- Employés
- 57 000
- Fondée
- 2012
- Actions en circulation
- Flottant
- 1.76 Md
- Capitalisation boursière
- 470.55 Md USD
- Initiés
- 0.11%
- Investisseurs institutionnels
- 77.37%
- Secteur d'activité (SIC)
- Pharmaceutical Preparations
- Forme juridique
- XTIQ
- ISIN
- US00287Y1091
- LEI
- FR5LCKFTG8054YNNRU85
- Taux de distribution
- 190%
- FCF
- 18.2 Md USD66%
- Dette
- 70.8 Md USD3.5 ans de FCF
- Ancienneté du dividende
- 13 ans
- Bénéfices, FCF et dividendes versés — pour les 12 mois précédant 30.06.2026 (le dernier rapport de l'entreprise).
Description
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Bourses et tickers
Dividendes
AbbVie Inc (ABBV) verse des dividendes trimestriels. Au cours des 12 derniers mois, 6.83 USD par action ont été versés (versements : 4). Cela représente environ 2.51% du cours actuel de l'action. La prochaine date ex-dividende est le 15.10.2026 : 1.73 USD par action, versement le 16.11.2026. Historique des dividendes ininterrompu : 13 ans.
| Date ex | Versement | Montant | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-10-15 annoncé | 2026-11-16 | 1.7300 USD | 0.6/2.5 % | trimestriel | US:ABBV |
| 2026-07-15 | 2026-08-14 | 1.7300 USD | 0.6/2.5 % | trimestriel | US:ABBV |
| 2026-04-15 | 2026-05-15 | 1.7300 USD | 0.6/2.5 % | trimestriel | US:ABBV |
| 2026-01-16 | 2026-02-17 | 1.7300 USD | 0.6/2.4 % | trimestriel | US:ABBV |
| 2025-10-15 | 2025-11-14 | 1.6400 USD | 0.6/≈2.4 % | trimestriel | US:ABBV |
| 2025-07-15 | 2025-08-15 | 1.6400 USD | 0.6/≈2.4 % | trimestriel | US:ABBV |
| 2025-04-15 | 2025-05-15 | 1.6400 USD | 0.6/≈2.4 % | trimestriel | US:ABBV |
Actualités de cette semaine
Communiqués de presse du site de l'entreprise pour les investisseurs, mis à jour chaque jour. Les liens mènent au site de l'entreprise. Les titres sont dans la langue originale, comme sur le site web de l'entreprise.
Principaux actionnaires
| Détenteur | Participation | Actions | Date du rapport |
|---|---|---|---|
| BlackRock | 8.46% | 149.49 M | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 115.4 M | 2026-06-30 |
| State Street Corporation | 4.67% | 82.6 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 56.09 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.74% | 48.48 M | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.71% | 47.86 M | 2026-06-30 |
| Geode Capital Management… | 2.66% | 47 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 45.78 M | 2026-06-30 |
| Morgan Stanley | 2.2% | 38.9 M | 2026-06-30 |
| Capital Research Global… | 1.7% | 30.1 M | 2026-06-30 |
| NORGES BANK | 1.45% | 25.55 M | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 23.84 M | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 22.85 M | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 21.61 M | 2026-08-31 |
| Bank of America Corporat… | 1.2% | 21.24 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 16.82 M | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 12.7 M | 2026-08-31 |
| AMERICAN MUTUAL FUND | 0.63% | 11.15 M | 2026-07-31 |
| Capital Income Builder | 0.57% | 10.06 M | 2026-07-31 |
| VANGUARD SPECIALIZED FUN… | 0.57% | 10 M | 2026-07-31 |
| GONZALEZ RICHARD A (Dire… | ≈0.02% | 386 479 | 2025-03-31 |
| SALEKI-GERHARDT AZITA (C… | ≈0.01% | 220 682 | 2026-02-18 |
| MICHAEL ROBERT A. (Chief… | ≈0.01% | 215 260 | 2026-02-18 |
| FREYMAN THOMAS C (Direct… | ≈0.01% | 135 751 | 2026-05-08 |
| STEWART JEFFREY RYAN (Of… | ≈0.01% | 108 321 | 2026-02-18 |
| DONOGHOE NICHOLAS (Offic… | ≈0% | 74 430 | 2026-08-14 |
| REENTS SCOTT T. (Chief F… | ≈0% | 60 415 | 2026-02-18 |
| THAKKAR ROOPAL (Officer) | ≈0% | 60 413 | 2026-02-18 |
| TILTON GLENN FLETCHER (D… | ≈0% | 51 914 | 2025-05-09 |
| RAPP EDWARD J (Director) | ≈0% | 45 964 | 2026-05-08 |
| The Vanguard Group | — | — | — |
